Trials / Completed
CompletedNCT05916573
A Study to Evaluate the Pharmacokinetics of HSK16149 in Subjects With Renal Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, single-dose study to evaluate the pharmacokinetics and safety of HSK16149 in subjects with mild, moderate and severe renal impairment compared to the matched control subjects with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HSK16149 | single oral adminiatration, 20mg |
Timeline
- Start date
- 2022-12-12
- Primary completion
- 2023-02-27
- Completion
- 2023-04-26
- First posted
- 2023-06-23
- Last updated
- 2023-06-23
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05916573. Inclusion in this directory is not an endorsement.